RGNX

+ Watchlist + Portfolio

REGENXBIO Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $11.06
52-Week Range: $5.46 – $16.19
Market Cap: $716.90M
P/E (TTM): —
EPS (TTM): -3.78
Dividend Yield: —

Advanced Metrics

Price/Book: 8.20
PEG Ratio: —
Return on Equity: -137.63%
Return on Assets: -21.20%
Gross Margin: -44.95%
Operating Margin: 27.09%
Profit Margin: -112.58%
Current Ratio: 2.86
Debt/Equity: 3.49
Total Debt: $250.46M
Free Cash Flow: $-184.26M
Revenue Growth: 405.70%
Earnings Growth: —
Enterprise Value: $875.05M

RGNX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$112.72M	$90.24M	$83.33M	$170.44M
Cost of Revenue	$54.55M	$37.21M	$33.57M	$20.30M
Gross Profit	$58.18M	$53.03M	$49.76M	$150.14M
Research & Development	$242.45M	$232.27M	$208.52M	$228.30M
Selling, General & Admin	$85.28M	$88.49M	$76.62M	$82.86M
Operating Expenses	$321.06M	$321.16M	$281.01M	$311.34M
Operating Income	-$262.88M	-$268.13M	-$231.25M	-$161.20M
EBITDA	-$244.24M	-$239.46M	-$198.23M	-$133.25M
Pretax Income	-$280.40M	-$263.65M	-$227.10M	-$193.88M
Income Tax	-$84.00K	-$152.00K	$0.00	—
Net Income	-$280.32M	-$263.49M	-$227.10M	-$193.88M
Diluted EPS	-6.50	-6.02	-4.59	-3.76
Diluted Shares	43.15M	43.73M	49.51M	51.57M

RGNX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$96.95M	$34.52M	$57.53M	$34.47M
Receivables	$30.29M	$26.34M	$21.57M	$27.38M
Current Assets	$415.98M	$334.97M	$278.00M	$281.28M
Total Assets	$833.27M	$573.97M	$465.99M	$453.03M
Current Liabilities	$130.43M	$130.27M	$103.19M	$118.09M
Total Debt	$94.80M	$89.29M	$82.03M	$73.50M
Total Liabilities	$317.07M	$262.23M	$206.34M	$350.30M
Retained Earnings	-$441.55M	-$705.05M	-$932.15M	-$1.13B
Shareholders' Equity	$516.20M	$311.74M	$259.65M	$102.73M
Working Capital	$285.54M	$204.70M	$174.81M	$163.19M

RGNX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$207.49M	-$218.41M	-$173.13M	-$123.96M
Capital Expenditure	-$30.72M	-$9.96M	-$2.44M	-$2.41M
Free Cash Flow	-$238.21M	-$228.37M	-$175.56M	-$126.38M
Depreciation & Amortisation	$12.91M	$17.32M	$16.21M	$15.62M
Stock-Based Compensation	$40.79M	$40.27M	$38.46M	$34.56M
Investing Cash Flow	-$11.93M	$190.94M	$103.45M	-$15.87M
Financing Cash Flow	-$28.84M	-$34.97M	$92.68M	$116.77M
Net Change in Cash	-$248.26M	-$62.43M	$23.00M	-$23.06M

RGNX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$89.01M	$21.36M	$29.73M	$30.34M	$6.39M
Cost of Revenue	$3.44M	$5.21M	$5.72M	$5.93M	$11.07M
Gross Profit	$85.58M	$16.15M	$24.01M	$24.41M	-$4.68M
Research & Development	$53.09M	$59.50M	$56.10M	$59.61M	$57.34M
Selling, General & Admin	$20.35M	$19.88M	$20.25M	$22.38M	$21.31M
Operating Expenses	$73.45M	$79.43M	$76.42M	$82.05M	$78.68M
Operating Income	$12.13M	-$63.28M	-$52.41M	-$57.64M	-$83.36M
EBITDA	$18.61M	-$55.97M	-$44.89M	-$51.00M	-$77.49M
Pretax Income	$6.08M	-$70.87M	-$61.94M	-$67.15M	-$90.05M
Net Income	$6.08M	-$70.87M	-$61.94M	-$67.15M	-$90.05M
Diluted EPS	0.12	-1.38	-1.20	-1.30	-1.72
Diluted Shares	51.43M	51.48M	51.69M	51.75M	52.43M

RGNX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$130.10M	$79.56M	$58.80M	$34.47M	$15.23M
Receivables	$19.16M	$21.49M	$26.47M	$27.38M	$10.94M
Current Assets	$313.24M	$373.75M	$331.97M	$281.28M	$186.52M
Total Assets	$490.93M	$581.03M	$525.20M	$453.03M	$341.89M
Current Liabilities	$106.73M	$119.54M	$124.57M	$118.09M	$71.11M
Total Debt	$79.85M	$77.70M	$76.51M	$73.50M	$71.07M
Total Liabilities	$216.73M	$367.35M	$363.75M	$350.30M	$320.81M
Retained Earnings	-$926.07M	-$996.94M	-$1.06B	-$1.13B	-$1.22B
Shareholders' Equity	$274.20M	$213.68M	$161.45M	$102.73M	$21.08M
Working Capital	$206.51M	$254.21M	$207.40M	$163.19M	$115.41M

RGNX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$33.63M	-$49.34M	-$55.96M	-$52.29M	-$76.19M
Capital Expenditure	-$1.02M	-$391.00K	-$491.00K	-$508.00K	-$1.24M
Free Cash Flow	$32.60M	-$49.73M	-$56.45M	-$52.80M	-$77.42M
Depreciation & Amortisation	$3.96M	$3.90M	$3.89M	$3.87M	$3.86M
Stock-Based Compensation	$8.54M	$8.65M	$9.00M	$8.38M	$8.62M
Investing Cash Flow	$44.74M	-$140.44M	$42.29M	$37.54M	$70.59M
Financing Cash Flow	-$5.79M	$139.23M	-$7.08M	-$9.58M	-$13.64M
Net Change in Cash	$72.58M	-$50.55M	-$20.76M	-$24.34M	-$19.24M

Market Snapshot

About

REGENXBIO is a clinical-stage biotechnology company developing gene therapies using its proprietary adeno-associated virus (AAV) platform. The company advances treatments for genetic diseases affecting the eye, liver, and central nervous system. REGENXBIO also licenses its NAV Technology Platform to other biotech and pharmaceutical companies, creating a dual revenue model from internal development and technology partnerships.